Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 34 of 34 publications.

Gibble TH, Sweeney C, Wolin D, McSorley D, Wang J, Koushik AK, Moses RE, Dubinsky MC. Real-world experience and perspectives on the treatment of crohn's disease: results from a healthcare provider survey. Poster presented at the 2023 Advances in Inflammatory Bowel Diseases (AIBD) Annual Meeting; December 14, 2023. Orlando, FL. [abstract] Am J Gastroenterol. 2023 Dec; 118(12S):S19.

Charabaty A, Gibble TH, Moses R, Sweeney C, Wolin D, McSorley D, Wang J, Rodriguez M, Park B, Dubinsky M. Assessing bowel urgency in clinical practice: results from a healthcare professional survey. Poster presented at the AJG 2023 Annual Scientific Meeting; October 24, 2023. Vancouver, Canada. [abstract] Am J Gastroenterol. 2023 Oct; 118(10S):S894-5. doi: 10.14309/01.ajg.0000954312.41350.0a

Carrillo N, Malicdan MC, Leoyklang P, Shrader JA, Joe G, Slota C, Perreault J, Heiss JD, Class B, Liu CY, Bradley K, Jodarski C, Ciccone C, Driscoll C, Parks R, Van Wart S, Bayman L, Coffey CS, Quintana M, Berry SM, Huizing M, Gahl WA. Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study. Genet Med. 2021 Nov;23(11):2067-75. doi: 10.1038/s41436-021-01259-x

Gold BD, Goodwin B, Davis K, Sweeney C, Ziemiecki R, Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Patient satisfaction and adherence to corticosteroids in adolescents and adults with eosinophilic esophagitis in a real-world setting in the US. Poster presented at the 2021 Annual Scientific Meeting & Postgraduate Course (ACG); October 24, 2021. Las Vegas, NV. [abstract] Am J Gastroenterol. 2021 Oct; 116:S177.

Gold BD, Goodwin B, Davis K, Sweeney C, Reynolds M, Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Health-related quality of life in adolescents and adults with eosinophilic esophagitis in a real world setting in the US. Poster presented at the 2021 Annual Scientific Meeting & Postgraduate Course (ACG); October 24, 2021. Las Vegas, NV. [abstract] Am J Gastroenterol. 2021 Oct; 116:S176. doi: 10.14309/01.ajg.0000774068.59482.1e

Gold BD, Goodwin B, Davis K, Sweeney C, Garbinsky D, Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Perceptions of disease stigma in adolescents and adults with eosinophilic esophagitis in the US. Poster presented at the 2021 Annual Scientific Meeting & Postgraduate Course (ACG); October 24, 2021. Las Vegas, NV. [abstract] Am J Gastroenterol. 2021 Oct; 116:S176-7. doi: 10.14309/01.ajg.0000774072.42679.92

Lewis MA, Stine A, Paquin RS, Mansfield C, Wood D, Rini C, Roche MI, Powell CM, Berg JS, Bailey, Jr DB. Parental preferences toward genomic sequencing for non-medically actionable conditions in children: a discrete-choice experiment. Genet Med. 2018 Feb;20(2):181-9. doi: 10.1038/gim.2017.93

Becker-Dreps S, Butler AM, McGrath LJ, Boggess KA, Weber DJ, Li D, Hudgens MG, Layton JB. Effectiveness of prenatal Tdap immunization in the prevention of infant pertussis in the US. Presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Adv Pharmacoepidemiol Drug Saf. 2018; 27(S2):169. doi: 10.1002/pds.4629

Kosa KM, Cates SC, Hall AJ, Brophy JE, Frasier A. Knowledge of norovirus prevention and control among infection preventionists. Poster presented at the 2014 APIC’s 41st Annual Conference; June 2014. Anaheim, CA. [abstract] Am J Infect Control. 2014 Jun; 42(6):676-8. doi: 10.1016/j.ajic.2014.02.004

Rothman KJ, Lanza LL. Estimated risks of fatal events associated with acetaminophen, ibuprofen, and naproxen sodium used for analgesia. Adv Pharmacoepidemiol Drug Saf. 2013 Jan 5;2(1):124.

Menzin J, Meyers JL, Friedman M, Korn JR, Perfect JR, Langston AA, Danna RP, Papadopoulos G. The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control. 2011 May 1;39(4):e15-20.

Yen L, Davis K, Longstreth G, Streck P, Hodgkins P. Resource utilization and health care costs associated with diverticulitis: results from a retrospective claims database analysis. Am J Gastroenterol. 2010 Oct 1;105(Suppl. 1):S431.

Nicandro JP, Tennis P, Bennett L, Hollis K, Shin P, Chuang E, Andrews E. Disability or restriction of daily activities is the most common indicator of disease severity in female patients with severe IBS-D: an analysis of the alosetron patient survey. Poster presented at the 2010 American College of Gastroenterology (ACG) Annual Scientific Meeting; October 2010. San Antonio, TX. [abstract] Am J Gastroenterol. 2010 Oct; 105(Suppl. 1):S410.

Menzin J, Marton JP, Meyers JL, Carson RT, Rothermel CD, Friedman M. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus. Am J Infect Control. 2010 Feb;38(1):44-9. doi: 10.1016/j.ajic.2009.04.287.

Carson R, Williams V, Nelson L, MacDougall J, Johnston J. Psychometric evaluation of patient-reported outcome measures for assessing IBS-c symptom severity and global change: results from a phase 2b study of linaclotide. Am J Gastroenterol. 2009 Oct 1;104:1113.

Mikkelsen EM, Wise LA, Riis A, Hatch EE, Sorensen HT, Rothman KJ. An internet-based prospective study of pregravid oral contraceptive use and time to pregnancy. Adv Pharmacoepidemiol Drug Saf. 2009 Aug 16;18(Suppl 1):S9.

Parijs BAV, Price M, Leon F, Fehnel S. Relevance of the gastrointestinal symptom rating scale (GSRS) in patients with celiac disease. Poster presented at the American College of Gastroenterology 2008 Annual Scientific Meeting and Postgraduate Course; October 2008. Orlando, FL. [abstract] Am J Gastroenterol. 2008 Sep 1; 103(Suppl. S):S395.

Earnshaw SR, McDade CL, Mangel AW, Baran RW. Cost-effectiveness of lubiprostone in a managed care population with chronic idiopathic constipation. Poster presented at the 2007 ACG Annual Meeting; September 2007. [abstract] Am J Gastroenterol. 2007 Sep; 102(S2):S449-50.

Mangel AW, Fehnel SE. Adequate relief in IBS treatment trials: corrections to errors stated by Whitehead et al. Am J Gastroenterol. 2006 Dec;101(12):2884-5.

Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2004;99:1-9.

Northcutt AR, Perschy TL, Ameen VZ, Hamedani AG, McSorley DJ, Carter EG. Most bothersome symptoms in irritable bowel syndrome (IBS) patients. Am J Gastroenterol. 2004;99(10):842.

Northcutt AR, Perschy TL, Ameen VZ, Hamedani AG, McSorley DJ, Carter EG. Correlating global outcome measures in Irritable Bowel Syndrome (IBS). Am J Gastroenterol. 2004;99(10):843.

Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol. 2001 Mar;96(3):803-11.

Schwartz HI, Perschy TB, McSorley DJ, Sorrells SC. Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. Am J Gastroenterol. 1999 Jun;4(2):121-7.

Mangel AW, Camilleri M, Chey WY, Hamm LR, Harding JP, Lawler C, McSorley DJ. Treatment of female IBS patients with alosetron, a potent and selective 5HT3-receptor antagonist. Am J Gastroenterol. 1999;116:G4505.

Mangel AW, Northcutt AR, Kong S, McSorley DJ. Validation of adequate relief as an endpoint in irritable bowel syndrome. Am J Gastroenterol. 1999;116:G4500.

Mangel AW, Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath AT, McSorley DJ. Alosetron, a 5-HT3 receptor antagonist, in the treatment of non-constipated female IBS patients. Am J Gastroenterol. 1999;94(9):2677.

Calvet X, Navarro M, Gil M, Lafont A, Sanfeliu I, Brullet E, Campo R, Dalmau B, Rivero E, Mas P. Epidemiology of peptic ulcer disease in cirrhotic patients: role of helicobacter pylori infection. Am J Gastroenterol. 1998 Dec;93(12):2501-7.

Vakil N, McSorley DJ, Hahn BA. Clarithromycin-resistant helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol. 1998 Sep;93(9):1432-5.

Ciociola AA, McSorley DJ. Consistent criteria should be employed in calculating h. pylori (HP) eradication rates: application of different published study criteria to ranitidine bismuth citrate (RBC) clinical trial data. Am J Gastroenterol. 1996;91(9):1907.

Graham DY, Hirshowitz B, Ciociola AA, Sykes DL, McSorley DJ. Ranitidine bismuth citrate plus amoxicillin for the treatment of duodenal ulcer disease. Am J Gastroenterol. 1995;90(9):638.

Johnson JA, Euler AR, Northcutt AR, McSorley DJ. Ranitidine 300mg at bedtime is effective for gastric ulcers: a 12-week, multicenter, randomized, double-blind, placebo-controlled comparison. Am J Gastroenterol. 1993;88(7):1071-5.

Marshall B, Ciociola AA, McSorley DJ, Webb DD. Computerized phone-in symptom recording system correlates with patient recorded symptom diary card for patients with non-ulcer dyspepsia. Am J Gastroenterol. 1993;91(9):1992.

Euler AR, Johnson JA, Dawson D, Kleoudis C, McSorley DJ. A comparison of ranitidine 150mg and placebo administered at bedtime for maintenance of recurrent benign gastric ulcers. Am J Gastroenterol. 1992;87(9):1267.